We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease--Advisory Committee on Immunization Practices (ACIP),2011.
- Abstract
The article reports on the decision of the U.S. Food and Drug Administration's (FDA) Advisory Committee on Immunication Practices (ACIP) to lower the approval range for use of Menveo, Novartis Vaccines and Diagnostics (MenACWY-CRM), a quadrivalent meningococcal conjugate vaccine, and its updated booster guidance for adolescents and other persons at increased risk for meningococcal disease. The ACIP recommends the immunization of children aged two through 10 years and adolescents 11 through 18 years. It also recommends a single booster dose of the vaccine for adolescents who received a previous dose before age 16, and a booster for persons aged two to 55 years. A randomized controlled trial showed the safety and immunogenecity of Men-ACWY-CRM in children aged two through 10 years.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration. Advisory Committee on Immunication Practices; MENVEO (Company); NOVARTIS Vaccines &; Diagnostics Inc.; MENINGOCOCCAL vaccines; IMMUNIZATION of children; RANDOMIZED controlled trials
- Publication
JAMA: Journal of the American Medical Association, 2012, Vol 307, Issue 1, p27
- ISSN
0098-7484
- Publication type
Article